The pharmaceutical industry has little incentive to invest in antibiotics because of the high risk and .
The potential financial returns are less likely to cover the cost of development than for other pharmaceuticals .
The pharmaceutical industry has little incentive to invest in antibiotics because of the high risk and because the potential financial returns are less likely to cover the cost of development than for other pharmaceuticals .